Establishment of serum Heparanase concentration measurement method and its application to gynecologic cancer treatment
| Project/Area Number |
20591955
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Obstetrics and gynecology
|
|---|
| Research Institution | University of the Ryukyus |
|---|
Principal Investigator |
AOKI Yoichi University of the Ryukyus, 医学研究科, 教授 (40231774)
|
|---|
| Co-Investigator(Renkei-kenkyūsha) |
INAMINE Morihiko 国立大学法人琉球大学, 医学研究科, 助教 (90437989)
|
|---|
| Project Period (FY) |
2008 – 2010
|
| Project Status |
Completed (Fiscal Year 2010)
|
| Budget Amount *help |
¥4,680,000 (Direct Cost: ¥3,600,000、Indirect Cost: ¥1,080,000)
Fiscal Year 2010: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2009: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2008: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Keywords | ヘパラナーゼ / 抗ヘパラナーゼ抗体 / 血清ヘパラナーゼ値 / 婦人科癌 / 転移抑制療法 / ELISA / 血清中ヘパラナーゼ値 / 婦人科がん患者 / 担癌患者 |
|---|
| Research Abstract |
To establish a measurement method of serum heparanase titer, we constructed ELISA system using antiHPR1 antibody, synthesized peptide for heparanase, and biotin-labeled peptide. The ELISA for heparanase measurement worked well in the reaction of the antibody and the synthesized peptide between concentrations of 10 to 1,000 nmol/l of HPR1 peptide. The ELISA also worked well in the measurement of serum heparanase between concentrations of 1 to 100nmol/l of HPR1 peptide. We tried to measure the 22 serum samples from patients with cervical cancer, endometrial cancer and ovarian cancer, and were able to get appropriate titers of heparanase concentration in each sample. These data indicate that our ELISA system for the measurement of serum heparanase titer is applicable for a clinical setting.
|
Report
(4 results)
Research Products
(53 results)
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Journal Article] Treatment and prognosis of brain metastases from gynecological cancers.2008
Author(s)
Ogawa K, Yoshii Y, Aoki Y, Nagai Y, Tsuchida Y, Toita T, Kakinohana Y, Tamaki W, Iraha S, Adachi G, Hirakawa M, Kamiyama K, Inamine M, Hyodo A, Murayama S.
-
Journal Title
Neurol Med Chir (Tokyo) 48
Pages: 57-63
NAID
Related Report
Peer Reviewed
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Long term follow-up of advanced ovarian cancer patients treated with biweekly paclitaxel/carboplatin (TC) combination chemotherapy.2010
Author(s)
Yoneyama K, Konishi H, Yahata T, Fujita K, Doi D, Honma S, Kodama, S Katoh H, Nakayama H, Kurose K, Aoki Y, Asakura H, Tanaka K, Takeshita T, Gynecologic Cancer Network.
Organizer
International Gynecological Cancer Society biannel meeting.
Place of Presentation
Prague
Related Report
-
[Presentation] Adjuvant paclitaxel and carboplatin in patients with complementaly or optimally resected carcinosarcomas (mixed mesodermal tumors) of the uterus.2010
Author(s)
Takano T, Otsuki T, Yaegashi N, Tase T, Nakahara K, Yokoyama Y, Aoki D, Nakayama H, Takehara H, Katabuchi H, Yamada H, Kikkawa F, Fujimoto T, Emoto M, Kamoi S, Arakawa A, Morimura Y, Hiura M, Aoki Y, Fujimoto H, Sato S, Kotera K, Japan Uterine Sarcoma Study Group.
Organizer
International Gynecological Cancer Society biannel meeting.
Place of Presentation
Prague
Related Report
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
[Presentation] Concurrent chemoradiotherapy using high-dose rate intracavitary brachytherapy for locoregionally advanced uterine cervical cancer.2008
Author(s)
Toita T, Nagai Y, Tamaki W, Ariga T, Kasuya G, Ogawa K, Kakinohana Y, Hirakawa M, Inamine M, Yagi C, Aoki Y, Murayama S.
Organizer
12^<th> Biennial meeting International Gynecologic Cancer Society Bangkok
Place of Presentation
Thailand
Related Report
-
-
-
-
-
-
-
-
-
-
